Cerca Biotech is at the forefront of innovative medical diagnostics, particularly in the realm of oncology and maternal health. Their flagship product, MammaTyper®, is a reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay designed for the molecular subtyping of breast cancer. This technology represents a significant advancement over traditional diagnostic methods that have remained largely unchanged for decades. MammaTyper® allows for reliable and rapid testing of tissue samples, ensuring accurate identification of breast cancer subtypes, which is crucial for determining appropriate treatment options and predicting patient prognosis. The assay utilizes a sophisticated algorithm to quantify key biomarkers, thereby minimizing variability and enhancing the precision of results.

In addition to breast cancer diagnostics, Cerca Biotech is developing the CercaTest RED™, a non-invasive, urine-based test aimed at ruling out Pre-Eclampsia. This point-of-care test is designed to be performed in community settings, providing results in a matter of minutes rather than days, which is essential for timely clinical decision-making. Both technologies reflect Cerca Biotech's commitment to leveraging practical and progressive techniques to transform healthcare, emphasizing the importance of early detection and accurate diagnosis in improving patient outcomes.

Germany

Cerca Biotech is a medical diagnostic company focused on bringing innovative  solutions to oncology and women’s health. We strive to introduce the best tests to meet clinical needs at an affordable cost, with accuracy and rapid results at the core.

Our focus is MammaTyper®, a reverse transcription-quantitative polymerase chain reaction PCR (RT-qPCR) assay and the first real innovation in breast cancer diagnostics for decades. MammaTyper® applies 21st century techniques to breast cancer subtyping, ensuring that every tissue sample is tested reliably, accurately, and quickly. 

Cerca Biotech

Company Details